SCHEMBL149814

SCHEMBL149814

O=C(O)c1cccc2c1N=C1CCCCC12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.37
▸ ALDH1A1 P00352 5/20 0.35
▸ GAA P10253 4/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ ALOX15 P16050 1/20 0.32
▸ CAMKK1 Q8N5S9 1/20 0.32
▸ CAMKK2 Q96RR4 1/20 0.32
▸ MAPK8 P45983 1/20 0.32
▸ NOS1 P29475 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ NOS3 P29474 1/20 0.32
▸ NOS2 P35228 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ MCL1 Q07820 1/20 0.32
▸ BRS3 P32247 2/20 0.32
▸ STS P08842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL148615 0.87 PARP1 (0.39) ALOX15
SCHEMBL6880796 0.72 ALDH1A1 (0.35) GFERALDH1A1GAAKDM4EMAPT
SCHEMBL145755 0.68 NOS1 (0.50) ALDH1A1KDM4ENOS1NOS3NOS2
SCHEMBL1925255 0.66 ALDH1A1 (0.52) ALDH1A1GAAKDM4EMAPTLMNA
SCHEMBL10790315 0.65 ACMSD (0.49) ALDH1A1KDM4EMAPTLMNAALOX15
SCHEMBL18091787 0.65 KMO (0.45) ALDH1A1GAAKDM4EMAPTLMNA
SCHEMBL2731512 0.64 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTLMNAALOX15
SCHEMBL10790290 0.64 ACMSD (0.50) ALDH1A1KDM4EMAPTLMNAALOX15
SCHEMBL11405090 0.64 ACMSD (0.44) ALDH1A1MAPTLMNAALOX15CAMKK1
SCHEMBL300805 0.64 ACMSD (0.50) ALDH1A1KDM4EMAPTLMNAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12084419-B2 Cell metabolism modulating compounds and uses thereof CRESCENTA BIOSCIENCES (US) 2024-09-10 — — US disclosed
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE CRESCENTA BIOSCIENCES (US) 2023-10-19 — — US disclosed
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS CRESCENTA BIOSCIENCES (US) 2023-08-17 — — US disclosed
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF CRESCENTA BIOSCIENCES (US) 2022-01-06 — — US disclosed
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 — — US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002243-A1 NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FABP4, FABP1, FABP3 GFER 3646/4885ALDH1A1 1176/4885GAA 1917/4885
US-12084419-B2 Cell metabolism modulating compounds and uses thereof FABP4, FABP1, FABP3 GFER 3391/4885ALDH1A1 982/4885GAA 1564/4885
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 GFER 4365/4885ALDH1A1 3832/4885GAA 3409/4885
US-20230331673-A1 COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE FABP4, FABP1, FABP3 GFER 3962/4885ALDH1A1 1236/4885GAA 1796/4885
US-20230255933-A1 ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS FABP1, FABP4, FABP5 GFER 3969/4885ALDH1A1 2082/4885GAA 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback